Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.500
Open
1.460
VWAP
1.48
Vol
84.00K
Mkt Cap
100.01M
Low
1.450
Amount
124.29K
EV/EBITDA(TTM)
--
Total Shares
67.58M
EV
1.95M
EV/OCF(TTM)
--
P/S(TTM)
--
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
Show More
3 Analyst Rating
508.11% Upside
Wall Street analysts forecast CLYM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLYM is 9.00 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
508.11% Upside
Current: 1.480
Low
7.00
Averages
9.00
High
10.00
508.11% Upside
Current: 1.480
Low
7.00
Averages
9.00
High
10.00
Oppenheimer
Oppenheimer
Outperform
initiated
$10
2025-06-06
Reason
Oppenheimer
Oppenheimer
Price Target
$10
2025-06-06
initiated
Outperform
Reason
BTIG
analyst
initiated
$7
2025-05-22
Reason
BTIG
analyst
Price Target
$7
2025-05-22
initiated
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Climb Bio Inc (CLYM.O) is -1.83, compared to its 5-year average forward P/E of -3.45. For a more detailed relative valuation and DCF analysis to assess Climb Bio Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.45
Current PE
-1.83
Overvalued PE
-1.56
Undervalued PE
-5.34
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
+665.99%
-23.02M
Operating Profit
FY2025Q1
YoY :
+1124.57%
-20.78M
Net Income after Tax
FY2025Q1
YoY :
+416.67%
-0.31
EPS - Diluted
FY2025Q1
YoY :
+748.49%
-15.43M
Free Cash Flow
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 1599.17% over the last month.
Sold
0-3
Months
26.7K
USD
2
3-6
Months
1.6K
USD
1
6-9
Months
2.5K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
1.1M
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
500.0K
Volume
Months
6-9
2
3.1M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 1599.17% over the last month.
Sold
0-3
Months
26.7K
USD
2
3-6
Months
1.6K
USD
1
6-9
Months
2.5K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CLYM News & Events
Events Timeline
2025-06-18 (ET)
2025-06-18
07:09:09
Climb Bio appoints Charles as CMO, Driscoll as SVP, Finance
2025-05-14 (ET)
2025-05-14
07:08:39
Climb Bio reports Q1 EPS (31c) vs (6c) last year
2025-04-01 (ET)
2025-04-01
07:15:39
Climb Bio appoints Kim Cobleigh Drapkin, Bo Cumbo to board
Sign Up For More Events
Sign Up For More Events
News
5.0
06-18NASDAQ.COMClimb Bio Names Edgar Charles CMO, Cindy Driscoll SVP-Finance
5.0
06-18NewsfilterClimb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer
4.0
06-07NASDAQ.COMOppenheimer Initiates Coverage of Climb Bio (CLYM) with Outperform Recommendation
Sign Up For More News
People Also Watch
MCRB
Seres Therapeutics Inc
15.410
USD
+15.00%
MNSB
MainStreet Bancshares Inc
21.280
USD
-0.09%
ULBI
Ultralife Corp
8.860
USD
+1.26%
QIPT
Quipt Home Medical Corp
2.120
USD
-3.20%
SLDB
Solid Biosciences Inc
6.810
USD
+1.95%
EUDA
EUDA Health Holdings Ltd
3.120
USD
0.00%
ZOM
Zomedica Corp
0.097
USD
0.00%
OPOF
Old Point Financial Corp
40.470
USD
-1.99%
LCTX
Lineage Cell Therapeutics Inc
1.155
USD
+0.43%
HURC
Hurco Companies Inc
19.700
USD
-0.30%
FAQ
What is Climb Bio Inc (CLYM) stock price today?
The current price of CLYM is 1.48 USD — it has increased 0 % in the last trading day.
What is Climb Bio Inc (CLYM)'s business?
What is the price predicton of CLYM Stock?
What is Climb Bio Inc (CLYM)'s revenue for the last quarter?
What is Climb Bio Inc (CLYM)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Climb Bio Inc (CLYM)'s fundamentals?
How many employees does Climb Bio Inc (CLYM). have?